What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer.

Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you. It is not known if LUMAKRAS® is safe and effective in children.

For US Audiences Only Approved Use Patient Information Full Prescribing Information Important Safety Information Select Cancer Type For Health Care Professionals

You are about to leave the lumakras.com/nsclc website and enter a website operated by a third party. Amgen is not responsible for and does not endorse or control the content contained on this third-party website.

Continue
Laurie S., a smiling current LUMAKRAS® patient

What is KRAS G12C?

If I didn’t advocate for myself, I wouldn’t have had testing and I would not have found out I was KRAS G12C positive.”

Patient story represents individual’s experience with LUMAKRAS®. Results may vary.

– Laurie S.
current LUMAKRAS® patient

What is a biomarker?

illustration of a human figure showing biomarkers found in tumor samples and blood

A biomarker is a molecule found in blood, other body fluids, or tissues, that is a sign of a normal or abnormal process, or of a condition or disease1

There are many different molecules that are considered biomarkers1

Knowing your biomarker status is an important step toward targeted treatment1

One biomarker that is present in some cancers,
including non-small cell lung cancer (NSCLC), is known as KRAS1-3
biomarkers-icon-1

KRAS is a biomarker we all have in our bodies. KRAS acts like an on/off switch that tells cells when to grow and when to stop growing1

KRAS is a biomarker in the context of cancer

Like many biomarkers, KRAS can mutate. Mutations are changes that occur in DNA. DNA is your body’s blueprint for its development and function1

One possible KRAS mutation in NSCLC is known as KRAS G12C1

What is a KRAS G12C mutation?

mutation-on

KRAS G12C is a mutant KRAS biomarker3

KRAS G12C causes that on/off switch to get stuck in the “on” position. This causes continuous and uncontrolled cell growth that can form tumors. Some tumors can be cancerous4

Approximately 1 in 8 people
with NSCLC have the KRAS G12C mutation5

about one in eight people with NSCLC have the KRAS G12C mutation.
patient-testimonial-image
Somebody who was just diagnosed, I would suggest that they get biomarker testing.”

– Laurie S.
current LUMAKRAS® patient

Patient story represents individual’s experience with LUMAKRAS®. Results may vary.

How do I find out if I have a KRAS G12C mutation?

  • Your doctor can test you for KRAS G12C by performing a biopsy. This is when a doctor takes a sample from your tumor or blood for testing. These are called tissue biopsies or liquid biopsies, depending on what type of sample is being examined1
  • Your doctor will help determine which test is right for you

If you have the KRAS G12C mutation, there is a treatment—LUMAKRAS®—designed for your type of lung cancer if you have already received at least one treatment2

To find out if you have KRAS G12C, ask your doctor for a biomarker test. Make sure your results are available whenever you’re discussing your treatment plan with your doctor2

Ask your doctor if you have the KRAS G12C mutation

Not actual patient.

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

  • Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
    • have liver problems.
    • have lung or breathing problems other than lung cancer.
    • are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the final dose.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
  • Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H2 blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

LUMAKRAS® may cause serious side effects, including:

  • Liver Problems: LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).
  • Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever.
  • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

The most common side effects

  • The most common side effects of LUMAKRAS® include diarrhea, muscle or bone pain, nausea, tiredness, liver problems, cough, changes in liver function tests, and changes in certain blood tests.
  • These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects.

What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer. Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you. It is not known if LUMAKRAS® is safe and effective in children.

Please see LUMAKRAS® full Prescribing Information.

References: 1. NCI Dictionary of Cancer Terms. www.cancer.gov. Accessed January 27, 2025. 2. LUMAKRAS® (sotorasib) prescribing information, Amgen. 3. Ryan MB, et al. Nat Rev Clin Oncol. 2018;15:709-720. 4. Hong DS, et al. N Engl J Med. 2020;383:1207-1217. 5. Data on file, Amgen; [Analysis of AACR Genie v12].

References: 1. Hong DS, et al. N Engl J Med. 2020;383:1207-1217. 2. NCI Dictionary of Cancer Terms. www.cancer.gov. Accessed January 27, 2025. 3. LUMAKRAS® (sotorasib) prescribing information, Amgen. 4. Sotorasib CSR. Amgen; 2021. 5. Data on file, Amgen; [KRAS G12C Trials Sites]. 6. LUMAKRAS® (sotorasib) patient information, Amgen.

References: 1. LUMAKRAS® (sotorasib) patient information, Amgen. 2. LUMAKRAS® (sotorasib) prescribing information, Amgen. 3. Data on file, Amgen; [Sotorasib Tablet Size].

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

  • Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
    • have liver problems.
    • have lung or breathing problems other than lung cancer.